HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis is a research paper published in JCI Insight (2022). On theSindex it has a DataRank of 0.520. It has been cited 31 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.520
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institute of Diabetes and Digestive and Kidney Diseases
Grant: R01DK100425
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: R01DK121710
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: P30DK057521
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: P30DK04620
American Heart Association
Grant: 16CSA28590003
American Diabetes Association
Grant: 1–19-PDF-088
American Diabetes Association
Grant: 1-16-INI-17
Eli Lilly and Company
Grant: sponsored research
NIDDK NIH HHS
Grant: P30 DK046200
NIDDK NIH HHS
Grant: P30 DK135043
National Institutes of Health
Grant: 5P30DK057521-09
CORE--RADIOIMMUNOASSAY/MONOCLONAL ANTIBODIES
National Institutes of Health
Grant: 1R01DK121710-01
Mechanisms connecting dysregulated BCAA, glucose & lipid metabolism in the pathogenesis of metabolic disease
National Institutes of Health
Grant: 5R01DK100425-08
The Role of ChREBP in Fructose Induced Metabolic Disease
FWCI
5.91
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia
Additional file 1 of Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia